Heart failure drug trial pulled before it even started
NCT ID NCT06795399
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study was designed to test an experimental drug called OPC-131461 in people hospitalized for worsening heart failure who still had fluid buildup after standard treatment. The goal was to see if the drug could improve a key blood marker of heart strain over 30 days. However, the trial was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- OPC-131461
- What this could lead to
- If it works, this could point toward a new oral treatment to help heart failure patients recover faster and reduce rehospitalization.
- What could go wrong
- The trial was withdrawn before enrolling any participants, so no data exists. Even if tested, early-phase results often fail to translate into real-world benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital nurse companion: could an app ease the burden of chronic illness?
- Could continuing a common heart drug before surgery save lives?
- Poles apart? nordic walking may outpace standard rehab for heart failure
- Could a gentler tug on the Heart's reins spark recovery?
- Can slow breathing soothe a failing heart?
- Can shedding pounds reboot the Heart's exercise engine?